All In Biotech

Drug Trial Radar · NCT07583849

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

A Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Inhalation Powder in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Design

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

May 24, 2026

Primary completion

Sep 30, 2027

Study completion Oct 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • HSK39004 Dry Powder Inhaler SimulantDrug

    HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily

  • HSK39004 Dry Powder Inhaler-0.75mgDrug

    HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curveTime frame: Week 12
  2. The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curveTime frame: week12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.